This is a summary of the European public assessment report (EPAR) for Myclausen. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Myclausen.
Therapeutic Indication
### Therapeutic indication Myclausen is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
Therapeutic Area (MeSH)
N/AATC Code
L04AA06
ATC Item
mycophenolic acid
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| mycophenolate mofetil | N/A | 吗替麦考酚酯 |
EMA Name
Myclausen
Medicine Name
Myclausen
Aliases
N/ANo risk management plan link.
